{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:58:24Z","timestamp":1781013504316,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comprehensive Psychiatry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.comppsych.2026.152704","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:34:22Z","timestamp":1777307662000},"page":"152704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world effectiveness of antipsychotic polytherapy on rehospitalization in psychotic disorders: A French nationwide cohort analysis"],"prefix":"10.1016","volume":"148","author":[{"given":"Pierre-Michel","family":"Llorca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Falissard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Baloche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Bournane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory","family":"Cals-Maurette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Panes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Nuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.comppsych.2026.152704_bb0005","unstructured":"Schizophrenia n.d. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schizophrenia (accessed September 7, 2023)."},{"key":"10.1016\/j.comppsych.2026.152704_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195687","article-title":"Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses","volume":"13","author":"Moreno-K\u00fcstner","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.comppsych.2026.152704_bb0015","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.schres.2017.05.015","article-title":"Correlates and predictors of antipsychotic drug polypharmacy in real-life settings: results from a nationwide cohort study","volume":"192","author":"Malandain","year":"2018","journal-title":"Schizophr Res"},{"key":"10.1016\/j.comppsych.2026.152704_bb0020","unstructured":"Orygen. Australian Clinical Guidelines for Early Psychosis - Second Edition Updated - Orygen, Revolution in Mind n.d. https:\/\/www.orygen.org.au\/Training\/Resources\/Psychosis\/Guidelines\/Australian-Clinical-Guidelines-for-Early-Psychosis (accessed September 19, 2025)."},{"key":"10.1016\/j.comppsych.2026.152704_bb0025","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/wps.20060","article-title":"Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies","volume":"12","author":"Kane","year":"2013","journal-title":"World Psychiatry"},{"key":"10.1016\/j.comppsych.2026.152704_bb0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-023-02175-z","article-title":"Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders","author":"Boyer","year":"2023","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.comppsych.2026.152704_bb0035","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s40265-021-01556-4","article-title":"Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations","volume":"81","author":"L\u00e4hteenvuo","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.comppsych.2026.152704_bb0040","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","article-title":"Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia","volume":"76","author":"Tiihonen","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.comppsych.2026.152704_bb0045","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamapsychiatry.2017.0624","article-title":"Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence","volume":"74","author":"Correll","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.comppsych.2026.152704_bb0050","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/wps.20387","article-title":"Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis","volume":"16","author":"Galling","year":"2017","journal-title":"World Psychiatry"},{"key":"10.1016\/j.comppsych.2026.152704_bb0055","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2019.05.030","article-title":"Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: a systematic review and meta-analysis","volume":"209","author":"Matsui","year":"2019","journal-title":"Schizophr Res"},{"key":"10.1016\/j.comppsych.2026.152704_bb0060","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.schres.2015.05.038","article-title":"The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial","volume":"166","author":"Constantine","year":"2015","journal-title":"Schizophr Res"},{"key":"10.1016\/j.comppsych.2026.152704_bb0065","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2013.10.034","article-title":"Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary","volume":"152","author":"Katona","year":"2014","journal-title":"Schizophr Res"},{"key":"10.1016\/j.comppsych.2026.152704_bb0070","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1176\/ps.2007.58.4.489","article-title":"Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns","volume":"58","author":"Kreyenbuhl","year":"2007","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.comppsych.2026.152704_bb0075","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00213-017-4767-6","article-title":"Antipsychotic polypharmacy prescribing and risk of hospital readmission","volume":"235","author":"Kadra","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.comppsych.2026.152704_bb0080","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/YIC.0b013e3281084ea8","article-title":"Factors associated with antipsychotic dosing in psychiatric inpatients: a prospective study","volume":"22","author":"Barbui","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2026.152704_bb0085","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1176\/appi.ajp.161.4.700","article-title":"Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits","volume":"161","author":"Centorrino","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.comppsych.2026.152704_bb0090","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2006.02.023","article-title":"Long-term combination antipsychotic treatment in VA patients with schizophrenia","volume":"84","author":"Kreyenbuhl","year":"2006","journal-title":"Schizophr Res"},{"key":"10.1016\/j.comppsych.2026.152704_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2023.01.009","article-title":"Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): how to translate guidelines into practice","author":"de Germay","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.comppsych.2026.152704_bb0100","doi-asserted-by":"crossref","unstructured":"Wiley Online Library. Comparison of pharmacy-based and diagnosis-based comorbidity measures from medical administrative data - Cortaredona - 2017 - Pharmacoepidemiol Drug Saf - n.d. https:\/\/doi.org\/10.1002\/pds.4146 (accessed July 15, 2021).","DOI":"10.1002\/pds.4146"},{"key":"10.1016\/j.comppsych.2026.152704_bb0105","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/MLR.0000000000000471","article-title":"The best use of the Charlson comorbidity index with electronic health care database to predict mortality","volume":"54","author":"Bannay","year":"2016","journal-title":"Med Care"},{"key":"10.1016\/j.comppsych.2026.152704_bb0110","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1203241","article-title":"Medication for attention deficit-hyperactivity disorder and criminality","volume":"367","author":"Lichtenstein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.comppsych.2026.152704_bb0115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12991-015-0053-3","article-title":"Revisiting loxapine: a systematic review","volume":"14","author":"Popovic","year":"2015","journal-title":"Ann General Psychiatry"},{"key":"10.1016\/j.comppsych.2026.152704_bb0120","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0013-7006(06)76188-7","article-title":"Therapeutics approach of adult patients with acute and chronic psychotic states: REALITE survey","volume":"32","author":"Cousin","year":"2006","journal-title":"Encephale"},{"key":"10.1016\/j.comppsych.2026.152704_bb0125","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.comppsych.2026.152704_bb0130","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1093\/schbul\/sby014.127","article-title":"31.1 optimising the treatment and management of FIRST-episode schizophrenia: the optimise clinical trial","volume":"44","author":"Kahn","year":"2018","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.comppsych.2026.152704_bb0135","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.comppsych.2026.152704_bb0140","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1176\/appi.ajp.159.2.180","article-title":"Amisulpride, an unusual \u201catypical\u201d antipsychotic: a meta-analysis of randomized controlled trials","volume":"159","author":"Leucht","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.comppsych.2026.152704_bb0145","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.comppsych.2026.152704_bb0150","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/schbul\/sbx176","article-title":"Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-a nationwide study with 20-year follow-up","volume":"44","author":"Taipale","year":"2018","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.comppsych.2026.152704_bb0155","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/14737175.2022.2108706","article-title":"Fifty years of experience with loxapine for the rapid non-coercive tranquilization of acute behavioral disturbances in schizophrenia patients, and beyond","volume":"22","author":"Nuss","year":"2022","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.comppsych.2026.152704_bb0160","unstructured":"PubMed. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis - n.d. https:\/\/pubmed.ncbi.nlm.nih.gov\/28127934\/ (accessed March 27, 2026)."},{"key":"10.1016\/j.comppsych.2026.152704_bb0165","doi-asserted-by":"crossref","first-page":"275","DOI":"10.9740\/mhc.2025.12.275","article-title":"Rational antipsychotic polypharmacy in psychotic and bipolar disorders: a focus on d2 receptor partial agonists","volume":"15","author":"Salwan","year":"2025","journal-title":"Ment Health Clin"},{"key":"10.1016\/j.comppsych.2026.152704_bb0170","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1176\/appi.ajp.20220446","article-title":"Safety of antipsychotic polypharmacy versus monotherapy in a nationwide cohort of 61,889 patients with schizophrenia","volume":"180","author":"Taipale","year":"2023","journal-title":"Am J Psychiatry"}],"container-title":["Comprehensive Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X2600043X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X2600043X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:00:29Z","timestamp":1781010029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010440X2600043X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":34,"alternative-id":["S0010440X2600043X"],"URL":"https:\/\/doi.org\/10.1016\/j.comppsych.2026.152704","relation":{},"ISSN":["0010-440X"],"issn-type":[{"value":"0010-440X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of antipsychotic polytherapy on rehospitalization in psychotic disorders: A French nationwide cohort analysis","name":"articletitle","label":"Article Title"},{"value":"Comprehensive Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.comppsych.2026.152704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152704"}}